Thus, our results indicate that trastuzumab induces the release of HER ligands and activation of HER receptors and trastuzumab monotherapy is not effective in decreasing cell growth in HER2-low MDA-MB-453 breast cancer cells. Here, ERBB2 is linked to breast carcinoma.